» Dr. Reza Mehvar
Professor, Chair of the Department of Biomedical and Pharmaceutical Sciences

School of Pharmacy
Dr. Reza Mehvar
Office Location:
Rinker Health Science Campus 257
(714) 516-5490
University of Tehran, Doctor of Pharmacy
University of Alberta, Ph.D.

Dr. Mehvar is the Professor and Chair of the Department of Biomedical and Pharmaceutical Sciences at Chapman University School of Pharmacy. Dr. Mehvar received his Pharm.D. degree from the University of Tehran College of Pharmacy (Tehran, Iran) and his Ph.D. in Pharmaceutical Sciences (Pharmacokinetics) from the University of Alberta Faculty of Pharmacy (Edmonton, Canada).

In 1988, Dr. Mehvar joined Drake University College of Pharmacy in Des Moines, IA (USA) as an Assistant Professor of Pharmaceutics where he was eventually promoted to Professor of Pharmaceutics prior to joining Texas Tech School of Pharmacy in 1999. At Texas Tech, he has served as Professor of Pharmaceutical Sciences, Interim Co-Chair of the Department of Pharmaceutical Sciences, and Director of the Pharmacokinetics Core of the Clinical Pharmacology & Experimental Therapeutics Center.

During his academic career, Dr. Mehvar has taught undergraduate and graduate pharmacokinetics courses and conducted research in the areas of pharmacokinetics, pharmacodynamics, hepatobiliary disposition of xenobiotics, and pharmacokinetic-based targeted drug delivery approaches. His laboratory research, which has been published in more than 100 peer-reviewed articles, has been consistently supported by several grants from the National Institutes of Health, pharmaceutical industry, and state and local foundations and agencies. Additionally, he has published 18 peer-reviewed educational articles related to ability-based learning approaches, online tools for active learning in pharmacokinetics, and curricular outcome assessment strategies.

Dr. Mehvar has received several awards for both his teaching and research accomplishments, including multiple American Association of Colleges of Pharmacy (AACP) Innovation in Teaching Awards, Texas Tech University Health Sciences Center President’s Excellence in Research Award, Texas Tech University Health Sciences Center President’s Excellence in Teaching Award, and Texas Tech University System Chancellor’s Council Distinguished Teaching Award. In recognition of his teaching accomplishments, recently (April 2014), Dr. Mehvar was inducted into the Academy of the Pharmacology Educators of the American Society for Pharmacology and Experimental Therapeutics (ASPET).

Research Interests

Dr. Mehvar’s research is focused on the role of the liver in drug disposition and the pharmacological approaches to treat liver diseases. With regard to drug disposition, recent studies in his laboratory have focused on the inflammatory mediators, such as cytokines and nitric oxide, affecting cytochrome P450-mediated drug metabolism. As for the liver diseases, the focus has been on the reduction of rejection in liver transplantation and attenuation of cold and warm ischemia-reperfusion (IR) injury. The latter studies have resulted in the development of a novel dextran prodrug of methylprednisolone, which selectively accumulates in the liver, releasing the active drug for an extended period of time (> two weeks) and reducing the IR injury and graft rejection after transplantation in animal models. Very recently, his laboratory has focused on the effects of hepatic IR injury on the transporter- and/or cytochrome P450-mediated hepatobiliary and brain disposition of drugs. In particular, his group is interested in investigating how liver diseases might affect the blood-brain barrier permeability and neurologic complications observed after liver surgical procedures. Dr. Mehvar also conducts educational research related to ability-based learning approaches, online tools for active learning in pharmacokinetics, and curricular outcome assessment strategies.

Recent Creative, Scholarly Work and Publications
Mehvar R. Fractional Clearance for Verapamil N-Demethylation in the Isolated Rat Liver Preparation. Drug Metab. Dispos. 43: 1056-1057 (2015).
Miah MK, Shaik IH, Bickel U, and Mehvar R. Effects of Pringle Maneuver and Partial Hepatectomy on the Pharmacokinetics and Blood-Brain Barrier Permeability of Sodium Fluorescein in Rats. Brain Res., 1618:249-260 (2015).
Mehvar R. Application of Organ Clearance to Estimation of the In Vivo Hepatic Extraction Ratio. Curr. Clin. Pharmacol., 2015 Aug 16. [Epub ahead of print]
Miah MK, Shaik IH, Bickel U, and Mehvar R. Effects of Hepatic Ischemia-Reperfusion Injury on the P-Glycoprotein Activity at the Liver Canalicular Membrane and Blood-Brain Barrier Determined by In Vivo Administration of Rhodamine 123 in Rats. Pharm. Res., 31:861-873 (2014).
Edpuganti, V and Mehvar R, UHPLC-MS/MS Analysis of Arachidonic Acid and 10 of Its Major Cytochrome P450 Metabolites as Free Acids in Rat Livers: Effects of Hepatic Ischemia. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 964: 153-163 (2014).
Holford S, Allegaert K, Anderson BJ, Kukanich B, Sousa AB, Steinman A, Pypendop B, Mehvar R, Giorgi M, and Holford N. Parent-Metabolite Pharmacokinetic Models for Tramadol – Tests of Assumptions and Predictions. J. Pharmacol. Clin. Toxicol. 2:1023 (2014).
Mehvar R, State of Current Clinical Pharmacology (Editorial). Curr. Clin. Pharmacol., 8:1-2 (2013).
Gupta V, Gupta N, Shaik IH, Mehvar R, McMurtry IF, Oka M, Nozik-Grayck E, Komatsu M, and Ahsan F. Liposomal Fasudil, a Rho-Kinase Inhibitor, for Prolonged Pulmonary Preferential Vasodilation in Pulmonary Arterial Hypertension. J. Control. Release. 167:189-199 (2013).
Gupta V, Gupta N, Shaik IH, Mehvar R, Grayck EN, McMurtry IF, Oka M, Komatsu M, and Ahsan F. Inhaled PLGA Particles of Prostaglandin E1 Ameliorate Symptoms and Progression of Pulmonary Hypertension at a Reduced Dosing Frequency. Mol. Pharm. 10:1655-1667 (2013).
Shaik IH, Miah MK, Bickel U, and Mehvar R. Effects of Short-Term Portacaval Anastomosis on the Peripheral and Brain Disposition of the Blood-Brain Barrier Permeability Marker Sodium Fluorescein in Rats. Brain Res., 1531:84-93 (2013).
Mehvar R, Confounding Issues in Estimation of Patient-Specific Pharmacokinetic Parameters and Dosage Individualization of Aminoglycosides. Curr. Clin. Pharmacol., 7:28-35 (2012).
Parasrampuria R, Shaik IH, and Mehvar R. Effects of In Vivo Hepatic Ischemia-Reperfusion Injury on the Hepatobiliary Disposition of Rhodamine 123 and Its Metabolites in Isolated Perfused Rat Livers. J. Pharm. Pharm. Sci., 15:318-328 (2012).
Mehvar R, Effects of Simulations on the Learning of Pharmacokinetic Concepts. Curr. Pharm. Teach. Learn., 4:278-284 (2012).
Shaik IH, Agarwal HK, Parang K, and Mehvar R. Hepatic Immunosuppressive Effects of Systemically-Administered Novel Dextran-Methylprednisolone Prodrugs with Peptide Linkers in Rats. J. Pharm. Sci., 101:4003-4012 (2012).
Mehvar R, The Importance of Active Learning and Practice on the Students' Mastery of Pharmacokinetic Calculations for the Intermittent Intravenous Infusion Dosing. BMC Med. Educ., 12: Article 116 (2012).
Pillai VC and Mehvar R, Inhibition of NADPH-Cytochrome P450 Reductase by Tannic Acid in Rat Liver Microsomes and Primary Hepatocytes: Methodological Artifacts and Application to Ischemia-Reperfusion Injury. J. Pharm. Sci., 100:3495-3505 (2011).
Shaik IH and Mehvar R, Effects of Normothermic Hepatic Ischemia-Reperfusion Injury on the In Vivo, Isolated Perfused Liver, and Microsomal Disposition of Chlorzoxazone, a Cytochrome P450 2E1 Probe, in Rats. J. Pharm. Sci., 100:5281-8292 (2011).
Pillai VC, Snyder RO, Gumaste U, Thekkumkara TJ, and Mehvar R, Effects of Transient Overexpression or Knockdown of Cytochrome P450 Reductase on Reactive Oxygen Species Generation and Hypoxia-Reoxygenation Injury in Liver Cells. Clin. Exp. Pharmacol. Physiol., 38:846-853 (2011).
Parasrampuria R and Mehvar R, Divergent Effects of Nitric Oxide Donors on the Biliary Efflux Transporters in Isolated Perfused Rat Livers: Nitric Oxide-Independent Inhibition of ABC Transporters by Sodium Nitroprusside. Drug Metab. Lett., 5:64-72 (2011).